PE20240223A1 - Composiciones farmaceuticas de un inhibidor de cinasa - Google Patents

Composiciones farmaceuticas de un inhibidor de cinasa

Info

Publication number
PE20240223A1
PE20240223A1 PE2023001561A PE2023001561A PE20240223A1 PE 20240223 A1 PE20240223 A1 PE 20240223A1 PE 2023001561 A PE2023001561 A PE 2023001561A PE 2023001561 A PE2023001561 A PE 2023001561A PE 20240223 A1 PE20240223 A1 PE 20240223A1
Authority
PE
Peru
Prior art keywords
compound
composition
pharmaceutical compositions
kinase inhibitor
present
Prior art date
Application number
PE2023001561A
Other languages
English (en)
Inventor
Iswadi Liejanto
Tzu-Yuan Chen
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of PE20240223A1 publication Critical patent/PE20240223A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion hace referencia a una composicion farmaceutica que comprende un compuesto inhibidor de cMet, N-(4-fluorofenil)-N-(4-((7-metoxi-6-(metilcarbamoil)quinolin-4-il)oxi)fenil)ciclopropano-1,1-dicarboxamida (Compuesto 1), uno o mas diluyentes, uno o mas aglutinantes, uno o mas disgregantes, uno o mas deslizantes, uno o mas lubricantes; y opcionalmente un recubrimiento de pelicula; el citado compuesto 1 puede estar presente en la composicion como un solido cristalino de base libre o como una sal cristalina farmaceuticamente aceptable. Tambien se refiere a procesos para producir dicha composicion, siendo util en el tratamiento de una enfermedad o trastorno proliferativo como el cancer.
PE2023001561A 2020-11-05 2021-11-04 Composiciones farmaceuticas de un inhibidor de cinasa PE20240223A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063110124P 2020-11-05 2020-11-05
PCT/US2021/057996 WO2022098828A1 (en) 2020-11-05 2021-11-04 Pharmaceutical compositions of a kinase inhibitor

Publications (1)

Publication Number Publication Date
PE20240223A1 true PE20240223A1 (es) 2024-02-16

Family

ID=78820880

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023001561A PE20240223A1 (es) 2020-11-05 2021-11-04 Composiciones farmaceuticas de un inhibidor de cinasa

Country Status (15)

Country Link
US (1) US20230398108A1 (es)
EP (1) EP4240333A1 (es)
JP (1) JP2023548855A (es)
KR (1) KR20230104186A (es)
CN (1) CN116406261A (es)
AU (1) AU2021374669A1 (es)
CA (1) CA3196001A1 (es)
CL (1) CL2023001268A1 (es)
CO (1) CO2023005942A2 (es)
CR (1) CR20230223A (es)
IL (1) IL302485A (es)
MX (1) MX2023005273A (es)
PE (1) PE20240223A1 (es)
TW (1) TW202227061A (es)
WO (1) WO2022098828A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3088200A1 (en) * 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
TW202334090A (zh) * 2021-11-03 2023-09-01 美商艾克塞里克斯公司 用於治療激酶依賴性病症之化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4014971A1 (en) * 2010-07-16 2022-06-22 Exelixis, Inc. C-met modulator pharmaceutical compositions
ES2927651T3 (es) * 2013-04-04 2022-11-10 Exelixis Inc Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer
WO2016079687A1 (en) * 2014-11-18 2016-05-26 Lupin Limited Oral pharmaceutical composition of teriflunomide
CA3088200A1 (en) 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
KR20210102381A (ko) 2018-12-13 2021-08-19 엑셀리시스, 인코포레이티드 키나아제 억제제의 결정질 형태 및 염 형태
EP3904356A4 (en) * 2018-12-24 2022-09-21 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. THERAPEUTIC USE OF PYRROLOPYRIMIDINE COMPOUND, AND SOLID PHARMACEUTICAL COMPOSITION OF PYRROLOPYRIMIDINE COMPOUND

Also Published As

Publication number Publication date
JP2023548855A (ja) 2023-11-21
KR20230104186A (ko) 2023-07-07
MX2023005273A (es) 2023-05-23
TW202227061A (zh) 2022-07-16
CA3196001A1 (en) 2022-05-12
AU2021374669A9 (en) 2024-04-18
EP4240333A1 (en) 2023-09-13
CL2023001268A1 (es) 2023-12-11
CN116406261A (zh) 2023-07-07
AU2021374669A1 (en) 2023-06-15
WO2022098828A1 (en) 2022-05-12
IL302485A (en) 2023-06-01
US20230398108A1 (en) 2023-12-14
CO2023005942A2 (es) 2023-05-19
CR20230223A (es) 2023-07-07

Similar Documents

Publication Publication Date Title
PE20240223A1 (es) Composiciones farmaceuticas de un inhibidor de cinasa
PE20211757A1 (es) Formas cristalinas y formas de sal de un inhibidor de cinasa
ECSP20001149A (es) Compuestos antiproliferativos y métodos para utilizarlos
UY39027A (es) Uso de favipiravir en el tratamiento de la infección por coronavirus
CY1118292T1 (el) Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων
BRPI1006812B8 (pt) Forma cristalina de l-malato de n-(4-{[6,7-bis(metiloxi)-quinolin-4-il]oxi}fenil)-n'-(4-fluorfenil)ciclopropano-1,1-dicarboxamida, composições farmacêuticas e usos do mesmo
CO2022012975A2 (es) Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
AR058338A1 (es) Derivados de pirrol fusionado, composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la quinasa.
PE20220962A1 (es) Formas de sales cristalinas de un inhibidor de cinasas
PE20110062A1 (es) N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo
CU20170026A7 (es) Compuestos derivados de 2-(benzamido/picolinamido/nicotinamido/isonicotinamido)-(2-metil-6-morfolino-(fenil/ (3,4´-bipiridin))-2-il)oxi)etil dihidrógeno fosfato como inhibidores de quinasa raf
AR057874A1 (es) Aminopirimidinas utiles como inhibidores de quinasa
BRPI0618479A2 (pt) pirrolpiridinas composição farmacêutica que as contém
CO6531452A2 (es) Piperidinas sustituidas que aumentan la actividad de p53 y sus usos
BRPI0515991A (pt) derivados de bisariluréia substituìda heterocìclica como inibidores de cinase
BR112016028819A2 (pt) composição farmacêutica, métodos para tratar uma doença ou condição em um ser humano e para inibir a atividade de um polipeptídeo de fosfatidilinositol 3-quinase e reações imunológicas excessivas ou destrutivas ou o crescimento ou a proliferação de células cancerosas, kit, composto, sal farmaceuticamente aceitável, isômero ou mistura dos mesmos, e, uso de um composto, sal farmaceuticamente aceitável ou mistura dos mesmos.
PE20161236A1 (es) Compuesto de triazina y su uso para fines medicos
CO2021005532A2 (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
AR112284A1 (es) Combinación que comprende palbociclib y ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxílico
MX2020004173A (es) Nueva combinacion de agentes activos para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas (pf-ild).
AR068845A1 (es) Composicion farmaceutica que contiene n-(3-metoxi-5-metilpirazin-2-il)-2-(4-((1,3,4-oxadiazol-2-il))fenil)piridin-3-sulfonamida util para el tratamiento del cancer
BR112022008786A2 (pt) Composto, composição, uso do composto ou da composição, e, método para tratar ou prevenir uma complicação diabética, doença relacionada à neuroinflamação ou aterosclerose
BRPI0607214B8 (pt) derivados de 2-(4-cianofenilamino)pirimidina inibidores de hiv, composição farmacêutica que os compreende e seus processos de preparação
AR123285A1 (es) Compuestos heteroarílicos sustituidos útiles como inhibidores de tlr9
AR126849A1 (es) Compuestos de quinazolina para tratamiento de enfermedad